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A 24 h pretreatment of human cultured fibroblasts with PAF-a&her (PAF) induced a decrease in LDL degradation 
and a correlative accumulation fundegraded LDL. LDL binding was not significantly affected. Sterol and triacylglycerol 
synthesis from sodium acetate was enhanced whereas phospholipid synthesis decreased. Oleic acid incorporation i to 
cholesteryl ester was markedly inhibited, whereas incorporation i to triacylglycerols was increased. A decrease in the 
percentage of phosphatidylcholine and an increase in the percentage of phosphatidylethanolamine were found using 
sodium P*P]orthophosphate as precursor. These effects of PAF on LDL and lipid metabolism could be related to pertur- 
bations in membrane structure characteristics, leading to a delay in LDL delivery to lysosomes, and to modification of 
the activity of some key enzymes of lipid metabolism. 
Low density lipoprotein; Platelet-activating factor; (Human fibroblast) 
1. INTRODUCTION 
PAF, or acetylglyceryl-ether-phosphorylcholine, 
is an ether phospholipid analog of phosphatidyl- 
choline and was first described as a mediator of 
platelet aggregation during immunoglobulin E- 
induced anaphylaxis in the rabbit [1,2]. Subse- 
quently, it was demonstrated that PAF is produced 
by a series of cell types (see [3] for review), 
especially by endothelial cells [4,5]. The increased 
adhesion and activation of both platelets and 
granulocytes at the endothelium surface might play 
a major role in the process of inflammation or in 
the formation of atherosclerotic plaques. 
The role of the LDL receptor pathway of 
fibroblasts in the appearance and extent of 
atherosclerosis was well established by Brown and 
Goldstein [6,7], in that a decrease in LDL receptor 
number, as observed in familial hypercholesterol- 
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emia [S], leads to premature atherosclerosis. After 
binding to the cell surface, the LDL particles are 
internalized by means of coated vesicles and en- 
dosomes [9]. The LDL particles then reach lyso- 
somes where degradation occurs. The liberated 
cholesterol in turn decreases endogenous 
cholesterol synthesis [lo], activates cholesterol 
esterification [I l] and inhibits the LDL receptor 
synthesis itself. 
In the current studies, the effects of PAF on 
LDL and lipid metabolism were investigated in 
cultured human fibroblasts. 
2. MATERIALS AND METHODS 
2.1. Materials 
PAF (DL-cu-phosphatidylcholine, ,&acetyl-r-0-hexadecyl), 
lyso PAF (DL-cu-lysophosphatidylcholine, y-0-hexadecyl) and 
,6-acetylphosphatidylcholine (L-a-phosphatidylcholine, ,8- 
acetyl-y-oleoyl) were from Sigma, St. Louis, MO, USA. 
Sodium [2-?]acetate, 55 mCi/mmol, and sodium [32P]or- 
thophosphate, 20 mCi/mg, were from CEA, Saclay, France; 
[l-‘4C]01eic acid, 52 mCi/mmol, and Na12’I, 13-17 Ci/mg, 
were from Amersham, Buckinghamshire, England. Dulbecco’s 
modified minimum essential medium (MEM) with Earle’s salts 
and fetal calf serum were from Gibco, Grand Island, NY. 
MRCS human fetal lung fibroblasts were purchased from 
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BioMtrieux, France. The serum substitute, Ultroser G, was 
from Industries Biologiques FranGaises, La Queue en Yvelines, 
France. Silica gel plates F 1500 were from Schleicher and 
Schull, Dassel, FRG. 
2.2. Cell culture 
Cells were cultured in 60 mm Nunc Petri dishes containing 
2 ml Dulbecco’s MEM supplemented with 20 mM Hepes buffer 
(pH 7.4), 100 units/ml penicillin, 100 yg/ml streptomycin and 
10% (v/v) fetal calf serum, at 37°C in a humidified atmosphere 
of 5% CO*. Experiments were performed on confluent cells. 
2.3. LDL preparation and labeling 
LDL was prepared from normal human serum according to 
Have1 et al. [12] and labeled according to Bilheimer et al. [13]. 
The specific radioactivity was 200-300 dpm/ng. 
2.4. Effect of PAF on LDL binding, internalization and 
degradation 
Cells were pretreated 24 h with PAF in ethanol solution (final 
concentration 0.5%) in medium supplemented with 2% 
Ultroser G for induction of LDL receptors. Cells were then 
washed 3 times, and LDL binding, internalization and degrada- 
tion studied according to [14], using 1Opg protein/ml lz51- 
LDL. Results are expressed in ng LDL/mg of cell protein. Pro- 
tein determination was done by the Lowry method. 
2.5. Effect of PAF on lipid metabolism 
Cells were preincubated 24 h with PAF in medium sup- 
plemented with either 2Vo Ultroser G (maximum sterol syn- 
thesis) for sodium acetate incorporation or 10% fetal calf serum 
(induction of cholesterol esterification). Then radioactive 
precursors, sodium acetate, 40 &i/ml, or oleic acid, 1 ,Ki/ml, 
resuspended in 0.2 mg/ml albumin were added. After a further 
4 h incubation, cells were washed 3 times and lipid analysis per- 
formed by thin-layer chromatography after application of a cell 
suspension aliquot to silica gel plates [IS]. The solvent system 
was hexane/diethyl ether/acetic acid (70: 30: 2, v/v) for neutral 
lipid analysis or chloroform/methanol/acetic acid/water 
(50: 30: 8 : 4, v/v) for phospholipid analysis. After autoradiog- 
raphy, the radioactive spots were cut out and counted by liquid 
scintillation with an Intertechnique instrument. Results are ex- 
pressed in pmol precursor incorporated/mg cellular protein. 
2.6. Effect of PAF on phospholipid composition 
Cells were grown for 48 h in the presence of lO,Ki/ml 
sodium [“PJorthophosphate, then further treated for 24 h with 
PAF (10e5 to 5 x lo-’ M) in the radioactive medium. After ex- 
tensive washing, lipid analysis was performed by thin-layer 
chromatography as described above. Results are expressed in 
percentages. 
Results were means of 4 or 6 experimental values f SD. 
Statistical analysis was performed by the Mann-Whitney- 
Wilcoxon test. 
3. RESULTS 
The effects of PAF on LDL metabolism are 
presented in table 1. It can be noted that whereas 
LDL binding, measured at 4”C, was not modified 
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Table 1 
Effects of platelet activating factor on LDL binding, uptake 
and degradation by cultured human fibroblasts 
Addition Membrane Intracellular 
bound (37°C) 
(4°C) 
Degraded 
(37°C) 
Control 45 + 4 192 + 13 936 i 91 
PAF 
IO-* M 42 + 5 240 + 18” 898 f 82 
2 x lO-5 M 46 + 4 257 * 23” 861 + 67 
5 x lO-5 M 43 f 3 303 + 3lb 618 + 51b 
Lyso PAF, 
5 x lO-5 M n.d. 196 f 11 951 * 79 
P-Acetylphosphatidyl- 
choline, 
5 x lO-5 M n.d. 193 * 14 942 + 71 
Cells were pretreated 24 h with PAF, lyso PAF or & 
acetylphosphatidylcholine in ethanol solution (final concen- 
tration of ethanol 0.5%) in lipoprotein-deficient Ultroser G 
supplemented medium for maximum induction of the LDL 
receptors. Binding, uptake and degradation were measured with 
10 pg/ml lz51-LDL. Results are expressed in ng LDL/mg cell 
protein. Means of 6 experimental values + SD. a p < 0.05; b p 
< 0.01 
after pretreatment of human fibroblasts with PAF, 
the cell-bound radioactivity measured at 37°C was 
increased in a dose-dependent manner to reach 
about 160% of control at 5 x 10e5 M PAF. In con- 
trast, LDL degradation was inhibited by PAF 
especially at the highest concentration and ac- 
counted only for 65% of control. It is of note that, 
in the same range of concentrations, lyso PAF or 
fl-acetylphosphatidylcholine did not significantly 
affect LDL internalization and degradation. 
Table 2 
Effects of platelet activating factor on lipid synthesis in cultured 
human fibroblasts 
Addition pmol precursor/mg protein incorporated into 
Sterols Triacylglycerols Phospholipids 
Control 465 + 52 1153 * 91 7585 + 571 
PAF 
IO-’ M 599 + 58a 1983 + 112b 6372 f 523 
2 x lO-5 M 744 k 62b 2721 f 189’ 5690 f 492” 
5 x 1O-5 M 837 f 74b 4312 & 319’ 4552 + 426” 
Cells were pretreated 24 h with PAF in Ultroser G- 
supplemented medium (maximum sterol synthesis) before 
addition of sodium acetate, 40 &i/ml, during 4 h. Means of 4 
experimental values + SD. a p < 0.05; b p < 0.01; ‘p < 0.001 
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Table 3 
Effects of platelet activating factor on oleic acid incorporation 
into cholesteryl esters, triacylglycerols and phospholipids in 
cultured human fibroblasts 
Addition pmol precursor/mg protein incorporated into 
Cholesteryl Triacylglycerols Phospholipids 
esters 
Control 396 f 32 2090 f 193 2043 + 158 
PAF 
IO-’ M 271 * 2ga 2404 + 197 1198 + 144 
2 x lO-5 M 249 + 19b 2822 f 218a 1594 + 135” 
5 x lO-5 M 154 + 13c 3971 f 254b 1511 + 97” 
Cells were pretreated 24 h with PAF in 10% fetal calf serum- 
supplemented medium (induction of the enzyme acyl coenzyme 
A : cholesterol acyltransferase) before addition of oleic acid, 
1 &i/ml, during 4 h. Means of 4 experimental values + SD. 
a p < 0.05; b p < 0.01; c p < 0.001 
The effects of PAF on lipid synthesis were fur- 
ther investigated and results are given in table 2. It 
can be seen that sterol synthesis from sodium 
acetate was increased by PAF pretreatment, 
together with a dose-dependent effect (180% of 
control at 5 x lo-’ M). Other lipid metabolism 
was also affected: triacylglycerol synthesis was 
markedly enhanced (3- to 4-fold), whereas 
phospholipid synthesis was decreased about 40%. 
Concerning cholesterol esterification studied by 
oleic acid incorporation into cholesteryl esters, the 
data from table 3 show that the esterification rate 
was diminished in the presence of PAF to about 
40% of control at 5 x lo-’ M. In contrast, oleic 
acid incorporation into triacylglycerols was 
enhanced (about a 2-fold increase was noted with 
5 x 10e5 M PAF), whereas incorporation into 
phospholipids was decreased by about 30%. 
As it can be assumed that some of the observed 
effects of PAF on LDL and lipid metabolism could 
be related to alterations of membrane physico- 
chemical characteristics, we thus investigated the 
effect of the mediator on phospholipid composi- 
tion. Table 4 shows that 2 x 10V5 M PAF 
significantly decreased the percentage of phospha- 
tidylcholine by about 20-2970, whereas that of 
phosphatidylethanolamine was increased by about 
35%. In cells treated with 5 x 10m5 M PAF, a 
decrease in the percentage of sphingomyelin was 
also observed. Concerning the percentage of 
phosphatidylinositol, a tendency to increase was 
noted at the highest concentration, but this 
phenomenon did not appear to be significant after 
statistical analysis. 
4. DISCUSSION 
In this work, it was demonstrated that PAF, 
while not affecting LDL binding, increased the in- 
tracellular radioactivity when cells were incubated 
at 37’C with lz51-LDL. However, as LDL degrada- 
tion was decreased in the presence of PAF, the on- 
ly explanation is that the mediator induces an 
accumulation of LDL, either on their way to 
lysosomes or within the lysosomes. It is of note 
that the formation of endosomes from coated 
vesicles and the fusion of endosomes with 
Table 4 
Effect of platelet-activating factor on phospholipid composition in cultured 
human fibroblasts 
Addition 
SM 
Percentage of 
PC PI PE 
None 10.8 + 1.2 58.1 f 4.2 9.3 + 1.5 21.8 + 3.3 
PAF 
lO-5 M 11.6 + 1.5 52.1 k 5.3 10.9 + 1.3 25.4 f 3.8 
2 x lO-5 M 10.3 + 1.0 47.2 zt 3.4a 12.0 * 1.7 30.5 + 3.1a 
5 x lo-’ M 8.2 f 0.8a 45.1 + 4.8a 12.7 + 1.8 34.0 * 5.4a 
Cells were grown during 48 h in 10% fetal calf serum-supplemented medium 
containing 10 ,Ki/ml sodium [“Plorthophosphate, 20 mCi/mg, and then 
further treated with PAF for 24 h in the presence of [“Plorthophosphate. 
Means of 4 experimental values f SD. a p < 0.05. SM, sphingomyelin; PC, 
phosphatidylcholine; PI, phosphatidylinositol; PE, phosphatidylethanolamine 
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lysosomes involve membrane movement and 
reorganization which might be modified by the 
presence of PAF, a phospholipid analog. 
Concerning cholesterol metabolism, the mediat- 
or PAF induced a stimulation of sterol synthesis 
and an inhibition of cholesterol esterification. It is 
well known that the rate of sterol synthesis is under 
the control of the key enzyme hydrox- 
ymethylglutaryl coenzyme A reductase [ 161, 
whereas the rate of cholesterol esterification is 
determined by the activity of acyl coenzyme 
A : cholesterol acyltransferase [171; both enzymes 
were localized in microsomal membranes and have 
been shown to be regulated by membrane micro- 
viscosity [ 18,191. In this regard, one might con- 
sider the hypothesis of an intercalation of PAF 
within the membrane phospholipids leading to 
modifications of membrane structure and physico- 
chemical characteristics, which in turn induce 
some perturbations in membrane-bound enzymatic 
activities. This hypothesis is further supported by 
the alterations in membrane phospholipid com- 
position observed in PAF-treated cells (table 4). It 
is noteworthy that the main feature observed is the 
decrease in phosphatidylcholine, which is located 
in the external leaflet of the membrane, whereas 
phosphatidylethanolamine, located in the internal 
leaflet, was decreased. 
The concentrations of PAF utilized in our cell 
system were relatively high. But it must be em- 
phasized that PAF is considered as a local 
mediator and that local concentrations within cell 
membranes might be markedly higher than ex- 
pected. Furthermore, it was recently demonstrated 
that preformed PAF is transported in blood bound 
to lipoproteins [20], and thus might be delivered to 
cells with great efficiency by means of the LDL 
receptor pathway. 
This work demonstrates that besides the well ad- 
mitted role of PAF in inflammation, this 
phospholipid mediator influences the LDL recep- 
tor pathway and cholesterol metabolism in 
cultured fibroblasts and hence might be involved in 
the pathogenic events leading to the formation of 
atherosclerotic plaques. 
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